- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on High Risk Smoldering Multiple Myeloma in United States
Total 2361 results
-
National Cancer Institute (NCI)CompletedMyeloma-Multiple | Myeloma, Plasma-CellUnited States
-
New York State Psychiatric InstituteTerminatedClinical High Risk for PsychosisUnited States
-
Gadeta B.V.Active, not recruitingMultiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma, RefractoryUnited States
-
National Cancer Institute (NCI)CompletedMyeloma-Multiple | Myeloma, Plasma-CellUnited States
-
University of Illinois at ChicagoNational Heart, Lung, and Blood Institute (NHLBI)CompletedStress, Psychological | Iron-deficiency | Pregnancy, High RiskUnited States
-
Elvira UmyarovaSanofiRecruitingRefractory Multiple Myeloma | Recurrent Multiple MyelomaUnited States
-
University of WashingtonGenzyme, a Sanofi CompanyRecruitingRefractory Multiple Myeloma | Recurrent Multiple MyelomaUnited States
-
Edwards LifesciencesTerminatedModerate to High-risk Noncardiac SurgeryUnited States
-
Abdullah KhanRecruitingRefractory Multiple Myeloma | Recurrent Multiple MyelomaUnited States
-
Mayo ClinicRecruitingRefractory Multiple Myeloma | Recurrent Multiple MyelomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingRefractory Multiple Myeloma | Recurrent Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage II Multiple Myeloma | Stage III Multiple MyelomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Blasts More Than 10 Percent of Bone Marrow Nucleated CellsUnited States
-
Icahn School of Medicine at Mount SinaiNational Institute of Mental Health (NIMH)RecruitingClinical High Risk for Psychosis (CHR)United States
-
University Hospitals Cleveland Medical CenterRainbow Babies and Children's HospitalCompleted
-
University of NebraskaM.D. Anderson Cancer CenterTerminatedCabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple MyelomaMultiple Myeloma | Refractory Multiple Myeloma | Relapsed/Refractory Multiple MyelomaUnited States
-
CASI Pharmaceuticals, Inc.CompletedRelapsed Multiple Myeloma | Plateau Phase Multiple MyelomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | High Risk Myelodysplastic SyndromeUnited States
-
Towson UniversityCompletedHigh Risk PregnancyUnited States
-
Mundipharma-EDO GmbHTerminatedMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma ProgressionSwitzerland, United States, Norway
-
Harpoon TherapeuticsActive, not recruitingMultiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma of BoneUnited States, France, Spain
-
US Oncology ResearchKaryopharm Therapeutics IncRecruitingMultiple Myeloma | Plasma Cell Myeloma | Myeloma-Multiple | Myeloma Multiple | Kahler Disease | Myeloma, Plasma Cell | MyelomatosisUnited States
-
Jonsson Comprehensive Cancer CenterWithdrawnRefractory Multiple Myeloma | Recurrent Multiple MyelomaUnited States
-
National Cancer Institute (NCI)RecruitingMultiple Myeloma | Relapsed and/or Refractory Multiple Myeloma (RRMM) | Newly Diagnosed Multiple Myeloma (NDMM)United States
-
Novartis PharmaceuticalsCompletedRefractory Multiple Myeloma | Multiple Myeloma in Relapse | Relapsed and Bortezomib Refractory Multiple MyelomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedRefractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Multiple Myeloma-Light Chain OnlyUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMyelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | IPSS Risk Category Intermediate-1United States
-
Deborah Farr, MDRecruitingBreast Cancer | High Risk of Breast CancerUnited States
-
University of Illinois at ChicagoNational Cancer Institute (NCI)RecruitingHigh Risk for Breast CancerUnited States
-
University of WashingtonGeneral ElectricCompletedArterial Occlusive Diseases | Hypertension | Pregnancy | Pregnancy, High Risk | Evidence of Liver TransplantationUnited States
-
National Cancer Institute (NCI)CompletedStage III Multiple Myeloma | Unspecified Adult Solid Tumor, Protocol Specific | Refractory Multiple MyelomaUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingHigh Risk for Developing Breast CancerUnited States
-
National Cancer Institute (NCI)Cancer and Leukemia Group BCompletedBreast Cancer | High Risk | Cyclophosphamide | Positive Nodes | DoxorubicinUnited States
-
University of Illinois at ChicagoCompletedMultiple Myeloma, Relapsed | Multiple Myeloma, Refractory to Standard TreatmentUnited States
-
National Cancer Institute (NCI)Georgetown University; Hackensack Meridian HealthTerminatedMyeloma-Multiple | Myeloma, Plasma-Cell | MyelomatosisUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); CelgeneRecruitingAcute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome With Excess Blasts | IDH2 Gene Mutation | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome | Blasts 20-30 Percent of Bone Marrow Nucleated CellsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedChronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Acute Myeloid Leukemia With Multilineage Dysplasia | Blasts 20-30 Percent of Bone Marrow Nucleated Cells | Blasts 20-30 Percent of Peripheral Blood White Cells | IPSS Risk Category Intermediate-2United States
-
University of New MexicoNational Institute of Mental Health (NIMH)CompletedPsychosis | Clinical High Risk for Psychosis | First Episode PsychosisUnited States
-
Rush University Medical CenterHarvard Medical School (HMS and HSDM); National Institute of Mental Health... and other collaboratorsCompletedClinical High Risk for PsychosisUnited States
-
Regeneron PharmaceuticalsActive, not recruitingRefractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical Center; Brigham and Women's Hospital; H. Lee Moffitt...CompletedMultiple Myeloma | Refractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States
-
Ionis Pharmaceuticals, Inc.Active, not recruitingRefractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States
-
M.D. Anderson Cancer CenterRecruitingAcute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome and other conditionsUnited States
-
Yale UniversityTerminatedClinical High Risk for PsychosisUnited States
-
Marcela V. Maus, M.D.,Ph.D.RecruitingMultiple Myeloma | Refractory Multiple Myeloma | Multiple Myeloma in RelapseUnited States
-
University of WashingtonRecruitingRefractory Multiple Myeloma | Plasma Cell Leukemia | Recurrent Multiple MyelomaUnited States
-
Alliance Foundation Trials, LLC.Pharmacyclics LLC.Active, not recruitingMultiple Myeloma | Refractory Multiple Myeloma | Multiple Myeloma in RelapseUnited States
-
National Cancer Institute (NCI)CompletedStage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Plasma Cell NeoplasmUnited States
-
Cartesian TherapeuticsRecruiting
-
Beth Israel Deaconess Medical CenterRecruitingClinical High Risk for PsychosisUnited States